CA3182864A1 - Procedes et compositions pour le traitement de la diarrhee induite par une chimiotherapie - Google Patents

Procedes et compositions pour le traitement de la diarrhee induite par une chimiotherapie

Info

Publication number
CA3182864A1
CA3182864A1 CA3182864A CA3182864A CA3182864A1 CA 3182864 A1 CA3182864 A1 CA 3182864A1 CA 3182864 A CA3182864 A CA 3182864A CA 3182864 A CA3182864 A CA 3182864A CA 3182864 A1 CA3182864 A1 CA 3182864A1
Authority
CA
Canada
Prior art keywords
crofelemer
cancer
chemotherapy
diarrhea
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3182864A
Other languages
English (en)
Inventor
Lisa A. CONTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Napo Pharmaceuticals Inc
Original Assignee
Napo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Napo Pharmaceuticals Inc filed Critical Napo Pharmaceuticals Inc
Publication of CA3182864A1 publication Critical patent/CA3182864A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes de traitement de la diarrhée par administration, à un patient qui en a besoin, d'un inhibiteur du transport des ions chlorure en une quantité suffisante pour traiter la diarrhée. Le traitement de la diarrhée comprend le traitement de la diarrhée ainsi que de la douleur, de l'inconfort abdominal et d'autres symptômes associés à la diarrhée. Dans un mode de réalisation, l'inhibiteur du transport des ions chlorure est le crofelemer.
CA3182864A 2020-06-19 2020-06-19 Procedes et compositions pour le traitement de la diarrhee induite par une chimiotherapie Pending CA3182864A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/038691 WO2021257089A1 (fr) 2020-06-19 2020-06-19 Procédés et compositions pour le traitement de la diarrhée induite par une chimiothérapie

Publications (1)

Publication Number Publication Date
CA3182864A1 true CA3182864A1 (fr) 2021-12-23

Family

ID=79268234

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3182864A Pending CA3182864A1 (fr) 2020-06-19 2020-06-19 Procedes et compositions pour le traitement de la diarrhee induite par une chimiotherapie

Country Status (10)

Country Link
EP (1) EP4168027A4 (fr)
JP (1) JP2023538186A (fr)
KR (1) KR20230027226A (fr)
AU (1) AU2020454132A1 (fr)
BR (1) BR112022025741A2 (fr)
CA (1) CA3182864A1 (fr)
IL (1) IL299028A (fr)
JO (1) JOP20220339A1 (fr)
MX (1) MX2022016367A (fr)
WO (1) WO2021257089A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115089592B (zh) * 2022-05-21 2024-02-27 复旦大学 多重酪氨酸激酶在制备抑制肠道病毒71型嗜神经性病毒药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011044167A1 (fr) * 2009-10-06 2011-04-14 University Of California, San Francisco Procédés de traitement de maladies par oligomères de proanthocyanidine tels que le crofelemer
PE20140036A1 (es) * 2010-10-31 2014-01-31 Napo Pharmaceuticals Inc Metodos y composiciones para tratar diarrea asociada con vih
US20160067311A1 (en) * 2014-09-10 2016-03-10 Helsinn Healthcare Sa Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
RU2017127686A (ru) * 2015-01-09 2019-02-11 Ягуар Хэлс, Инк. Способы лечения диареи у домашних животных
JP2020513410A (ja) * 2016-12-06 2020-05-14 カレイド・バイオサイエンシズ・インコーポレイテッド グリカンポリマーおよびその関連方法

Also Published As

Publication number Publication date
EP4168027A4 (fr) 2024-04-03
EP4168027A1 (fr) 2023-04-26
IL299028A (en) 2023-02-01
BR112022025741A2 (pt) 2023-01-03
WO2021257089A1 (fr) 2021-12-23
KR20230027226A (ko) 2023-02-27
MX2022016367A (es) 2023-01-30
JP2023538186A (ja) 2023-09-07
AU2020454132A1 (en) 2023-02-02
JOP20220339A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
AU2020222296B2 (en) Pharmaceutical combination comprising TNO155 and ribociclib
Heist et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer
US10973829B2 (en) Therapeutic uses of a C-RAF inhibitor
Ricci et al. Drug-induced hair colour changes
CN108024540A (zh) 用于治疗癌症的方法
US20220362209A1 (en) Methods and compositions for treating chemotherapy-induced diarrhea
RU2738934C2 (ru) Способы лечения рака с использованием апилимода
EP3215157B1 (fr) Apilimod destiné à être utilisé dans le traitement du mélanome
DK2605764T3 (en) Compositions for the treatment of cancer
CN108025035A (zh) 用于治疗与etbr激活相关的癌症的组合物和方法
JP6860949B2 (ja) 癌の処置方法
Okada et al. Evaluation of the efficacy of daikenchuto (TJ-100) for the prevention of paralytic ileus after pancreaticoduodenectomy: A multicenter, double-blind, randomized, placebo-controlled trial
KR20210010524A (ko) 샘낭암종을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물
CA3182864A1 (fr) Procedes et compositions pour le traitement de la diarrhee induite par une chimiotherapie
US20200297671A1 (en) Methods of avoiding excipient-based adverse effects and of exploiting biological properties of gras compounds
TW202200127A (zh) 用於治療化學療法引起的腹瀉之方法及組合物
CN108495633A (zh) 使用阿吡莫德治疗癌症的生物标记
BR112021008606A2 (pt) uso de tivozanibe para tratar indivíduos com câncer refratário
Scanga et al. Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma?
RU2729425C2 (ru) Дозы панобиностата для множественной миеломы
JP2019529556A (ja) 血管遮断剤として有用なベンゾフェノンチアゾール誘導体およびトポイソメラーゼ抑制剤を含む癌の予防または治療用薬学的調合物
WO2024023766A1 (fr) Polythérapie à base d'inhibiteur de p13k
Simoneaux et al. American Society of Clinical Oncology-51st Annual Meeting. Chicago, Illinois, USA-May 29-June 2, 2015
Nag mTOR inhibition in management of advanced breast cancer
JP2019131559A (ja) 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ